TWIST BIOSCIENCE Reports Fourth Quarter FY2023 Earnings Results for Period Ending November 17 2023
November 28, 2023
🌥️Earnings Overview
TWIST BIOSCIENCE ($NASDAQ:TWST) reported total revenue of USD 67.0 million for the fourth quarter of FY2023, which ended on November 17 2023, a 16.8% increase from the same quarter of the prior year. Reported net income in the fourth quarter was USD -46.2 million, a decline of 51.1 million from the same quarter in the previous year.
Price History
On Friday, TWIST BIOSCIENCE reported its earnings results for the fourth quarter of its fiscal year 2023. The company’s stock opened at $20.6 and closed at $24.0 for the period ending November 17th, a soar of 25.9% from the previous closing price of 19.1. This marks a strong end to the fiscal year for TWIST BIOSCIENCE, with the company’s stock prices climbing to a high that hasn’t been seen in years. Analysts attribute the rise to TWIST BIOSCIENCE’s commitment to developing new technologies that will differentiate the company from competitors and increase its value in the marketplace. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Twist Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 245.11 | -204.62 | -80.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Twist Bioscience. More…
| Operations | Investing | Financing |
| -123.04 | -232.93 | 270.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 776.4 | 152.97 | 11.46 |
Key Ratios Snapshot
Some of the financial key ratios for Twist Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.6% | – | -83.0% |
| FCF Margin | ROE | ROA |
| -67.3% | -19.3% | -16.4% |
Analysis
At GoodWhale, we performed an analysis of TWIST BIOSCIENCE‘s wellbeing. Our Star Chart showed that, considering its cashflows and debt, TWIST BIOSCIENCE had an intermediate health score of 4/10, indicating that they might be able to pay off debt and fund future operations. Our analysis of TWIST BIOSCIENCE’s performance found that they are strong in asset and growth and weak in dividend and profitability. We classified TWIST BIOSCIENCE as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Based on this, we conclude that investors interested in TWIST BIOSCIENCE should have a higher risk tolerance due to the company’s unstable nature, and should be prepared for potential volatility in the future. More…
Peers
It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.
– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)
FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.
FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.
FoundHTG has a market cap of $6.07M and a ROE of -156.17%.
– Proteome Sciences PLC ($LSE:PRM)
Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.
– Genedrive PLC ($LSE:GDR)
Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.
Summary
Investors in TWIST BIOSCIENCE saw a positive response to the company’s fourth quarter FY2023 earnings results, announced September 30 2023. Total revenue for the quarter increased 16.8% year-over-year to USD 67.0 million.
However, reported net income for the quarter was USD -46.2 million, a decrease of -51.1 million from the same quarter in the prior year. Despite the decrease in income, TWIST BIOSCIENCE’s stock price moved up the same day, indicating that investors are confident in the company’s future performance. This suggests that investors should think about investing in TWIST BIOSCIENCE for potential long-term returns.
Related Posts
Recent Posts
